Applying a Congruent Oncology Pharmacy Strategy – From Guidelines to Specialty Pharmacy: Steps for Success with Multiple Myeloma Web Archive

Track 1: Optimizing Therapeutic Decision-Making for Multiple Myeloma: A Clinical Overview

Track 2: Supportive Care Needs and Collaborative Strategies for Patients with Multiple Myeloma

Track 3: Managed Care Strategies for the Management of Multiple Myeloma

• Part 1: Oncology Pharmacy Benefit Management
• Part 2: Decision Support Tools

• Release date: August 1, 2013
• Expiration date: February 28, 2015
• Estimated Time to Complete Activity: 0.75 CME and CPE hours (Track 1); 0.75 CME and CPE (Track 2); 1.0 CME and CPE (Track 3)
• Compatible with (IE 6 and up, Firefox, Safari)

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for hemophilia patients including: physicians, pharmacists, registered nurses, and case managers

STATEMENT OF NEED/PROGRAM OVERVIEW

Oncology is often characterized by small trials, phase 2 data, surrogate efficacy endpoints (i.e., depth of response, time to progression), and relatively little data regarding “hard” endpoints, such as overall survival (OS). The nature of cancer also creates unique implications for how comparative effectiveness research (CER) should be ap¬plied. Enhanced competency is needed regarding the structure and delivery of oncology benefit designs, including supportive care. This curriculum will illustrate a systematic approach to evaluate, select, and implement specialty pharmacy benefit design and management services to improve access and outcomes to appropriate therapies for patients with cancers such as multiple myeloma (MM).

TRACK 1 EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Review current and emerging clinical data to optimize therapeutic decision-making based on indicators of efficacy outcomes for MM treatments
• Provide accurate and appropriate counsel as part of the managed care treatment team

TRACK 2 EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Recommend methods to improve MM patient outcomes with supportive care within a health plan setting
• Provide accurate and appropriate counsel as part of the managed care treatment team

TRACK 3 EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Demonstrate the use of CER as a decision-support tool to appropriately invest resources and reduce treatment variability with MM therapies
• Evaluate innovative oncology pharmacy benefit models and specialty management services
• Provide accurate and appropriate counsel as part of the managed care treatment team

TRACK 1 - DISTINGUISHED FACULTY

Amrita Y. Krishnan, MD, FACP Director, Multiple Myeloma Program Associate Director, Medical Education & Training Hematology & Hematopoietic Cell Transplantation Member, Hematologic Malignancies Program, Comprehensive Cancer Center Associate Professor of Hematology/HCT City of Hope Click here for biography

Sandra Kurtin, RN, MS, AOCN®, ANP-C Hematology/Oncology Nurse Practitioner The University of Arizona Cancer Center Clinical Assistant Professor of Medicine Adjunct Clinical Assistant Professor of Nursing University of Arizona Click here for biography

TRACK 2 - DISTINGUISHED FACULTY

Sandra Kurtin, RN, MS, AOCN®, ANP-C Hematology/Oncology Nurse Practitioner The University of Arizona Cancer Center Clinical Assistant Professor of Medicine Adjunct Clinical Assistant Professor of Nursing University of Arizona Click here for biography

Atheer Kaddis, PharmD Senior Vice President, Sales and Business Development Diplomat Specialty Pharmacy Click here for biography

TRACK 3 - DISTINGUISHED FACULTY

Atheer Kaddis, PharmD Senior Vice President, Sales and Business Development Diplomat Specialty Pharmacy Click here for biography

James Kenney, Jr., RPh, MBA, Activity Chairperson Pharmacy Operations Manager Harvard Pilgrim Healthcare, Inc. Click here for biography

ACCREDITATION

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation (all tracks)
Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• Track 1 - 0.75 CME credits
• Track 2 - 0.75 CME credits
• Track 3 – 1.0 CME credits

Pharmacist Accreditation Statement

	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation (all tracks)
Postgraduate Institute for Medicine designates this continuing education activity for 2.5 contact hours (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

• Track 1-Universal Activity Number: 0809-9999-13-257-H01-P, 0.75 contact hours
• Track 2-Universal Activity Number: 0809-9999-13-258-H01-P, 0.75 contact hours
• Track 3-Universal Activity Number: 0809-9999-13-259-H01-P, 1.0 contact hours

Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period August 1, 2013 through February 28, 2015, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the embedded questions within the activity; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Media
Internet

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

TYPE OF ACTIVITY
Track 1 - Knowledge
Track 2 - Knowledge
Track 3 - Knowledge

FEE INFORMATION
There is no fee for this educational activity.